Esophagogastric Adenocarcinoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2017-05-09
Clinical Trial Update: Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) [Phase 2]
A Phase 2 trial of nintedanib plus mFOLFOX6 for previously untreated metastatic esophagogastric adenocarcinoma has been withdrawn.